Standard Diagnostics, Inc. engages in developing, manufacturing, and marketing rapid disease test kits. It offers home health care equipment, such as various rapid test kits to test blood borne diseases, sexually transmitted diseases, malaria, dengue fever, febrile diseases, tuberculosis, respiratory diseases, gastrointestinal infection, fertility harmones, drug of abuse, and bio-terror, as well as cancer markers, cardiac makers, and forensic tests. The company also provides ELISA kits for testing infectious diseases; and urine test products, including urine strips and urine analyzers. In addition, it offers SD BIOLINE HIV/Syphilis Duo test, a solid phase immunochromatographic assay for the ...
Founded in 1999
Foundation for Innovative New Diagnostics and Standard Diagnostics, Inc. to Co-Develop Second Generation Rapid Test for Human African Trypanosomiasis
Apr 23 14
FIND (Foundation for Innovative New Diagnostics) and the University of Dundee have signed a Material Transfer Agreement under which new reagents developed by the University will be made available for the development of an improved version of a rapid test for sleeping sickness, a deadly parasitic disease also known as Human African Trypanosomiasis (HAT). A first generation rapid test for HAT was developed by FIND and partners and made commercially available in September 2013. This test is manufactured by Standard Diagnostics, Inc. (SD) and is being introduced in multiple endemic countries as part of new diagnostic strategies to improve early detection of HAT patients. The second generation rapid test will be co-developed by SD and FIND, and will include new antigens that were developed by the University of Dundee and BBI Solutions, who demonstrated their diagnostic potential in prototype rapid tests for sleeping sickness. The new test is planned to be launched in early 2015. Sustainable, large-scale production of the second generation test will be possible because unlike the first generation one it is based on a new format of antigens that are easier to produce. As a result the new test is also expected to be more affordable than the current one.